|
AU2019332882A1
|
|
Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide
|
|
WO2019239374A1
|
|
Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
|
|
WO2018134786A1
|
|
Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase
|
|
EA037031B1
|
|
Imidazopyrazine inhibitors of bruton's tyrosine kinase
|
|
KR20190095403A
|
|
Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase
|
|
WO2018115965A1
|
|
Solid forms of imidazopyrazine compounds
|
|
AU2017368331A1
|
|
Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
|
|
US2017224688A1
|
|
Methods of Using BTK Inhibitors to Treat Dermatoses
|
|
US2019008869A1
|
|
Therapeutic Combinations of an Antifolate and a BTK Inhibitor
|
|
CN108602827A
|
|
The Imidazopyrazines inhibitor of Bruton tyrosine kinase
|
|
US2017035881A1
|
|
Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor
|
|
US2019022092A1
|
|
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
|
EP3747472A1
|
|
Therapeutic combinations of a cd19 inhibitor and a btk inhibitor
|
|
US2017071962A1
|
|
Therapeutic Combinations of a Proteasome Inhibitor and a BTK Inhibitor
|
|
US2019008859A1
|
|
Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
|
|
CA2991096A1
|
|
Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
|
|
WO2016128912A1
|
|
Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor, and/or a pd-l1 inhibitor
|
|
WO2016087994A1
|
|
Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
|
|
WO2016055982A1
|
|
Quinoline and quinazoline compounds
|
|
TW201618775A
|
|
Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, a PD-1 inhibitor and/or a PD-L1 inhibitor
|
